Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (141-150 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Heart Failure|November 11, 2003
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)Jay N Cohn, Marc A Pfeffer, Jean Rouleau, et al.
European Journal of Heart Failure|September 25, 2007
Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysisMitja Lainscak, John G F Cleland, Mattie J Lenzen, et al.
Scandinavian Journal of Primary Health Care|September 17, 2004
Can brain natriuretic peptide (BNP) be used as a screening tool in general practice?Maria Schaufelberger, Claes-Håkan Bergh, Kenneth Caidahl, et al.
The American Journal of Cardiology|March 24, 2007
Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure SurveyMitja Lainscak, John G F Cleland, Mattie J Lenzen, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 3, 2010
Heart rate reduction in cardiovascular disease and therapyJan-Christian Reil, Florian Custodis, Karl Swedberg, et al.
The Canadian Journal of Cardiology|February 3, 2005
Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failureEric B Stanton, Mark S Hansen, Michael J Sole, et al.
Journal of the American College of Cardiology|April 28, 2012
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) studyKarl Swedberg, Faiez Zannad, John J V McMurray, et al.
Circulation. Heart Failure|April 30, 2013
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF studyHenry Krum, Harry Shi, Bertram Pitt, et al.
ESC Heart Failure|April 6, 2024
Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARMHailun Qin, Pooja Dewan, Bernadet T Santema, et al.
Journal of Electrocardiology|July 18, 2002
QRS aberration during atrial fibrillation at rest and during exercise. Effect of a selective potassium channel blocking agentBirgitta Houltz, Börje Darpö, Harry J G M Crijns, et al.
Pageof 48

Showing results (141-150 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Heart Failure|November 11, 2003
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)Jay N Cohn, Marc A Pfeffer, Jean Rouleau, et al.
European Journal of Heart Failure|September 25, 2007
Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysisMitja Lainscak, John G F Cleland, Mattie J Lenzen, et al.
Scandinavian Journal of Primary Health Care|September 17, 2004
Can brain natriuretic peptide (BNP) be used as a screening tool in general practice?Maria Schaufelberger, Claes-Håkan Bergh, Kenneth Caidahl, et al.
The American Journal of Cardiology|March 24, 2007
Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure SurveyMitja Lainscak, John G F Cleland, Mattie J Lenzen, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 3, 2010
Heart rate reduction in cardiovascular disease and therapyJan-Christian Reil, Florian Custodis, Karl Swedberg, et al.
The Canadian Journal of Cardiology|February 3, 2005
Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failureEric B Stanton, Mark S Hansen, Michael J Sole, et al.
Journal of the American College of Cardiology|April 28, 2012
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) studyKarl Swedberg, Faiez Zannad, John J V McMurray, et al.
Circulation. Heart Failure|April 30, 2013
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF studyHenry Krum, Harry Shi, Bertram Pitt, et al.
ESC Heart Failure|April 6, 2024
Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARMHailun Qin, Pooja Dewan, Bernadet T Santema, et al.
Journal of Electrocardiology|July 18, 2002
QRS aberration during atrial fibrillation at rest and during exercise. Effect of a selective potassium channel blocking agentBirgitta Houltz, Börje Darpö, Harry J G M Crijns, et al.
Pageof 48